The Patent Finder
US

Selection of Non-Small-Cell Lung Cancer Patients for Treatment with Monoclonal Antibody Drugs Targeting Egfr Pathway

US 7,858,389 Term ended
OverviewFamilyAssignmentsSources & methods
Collateral for a security interest recorded Feb 27, 2018 (Biodesix, Inc.).

Term ended no later than Jun 2, 2026 · Medium confidence

Filed Jan 20, 2009 as application 12/321,392 · Granted Dec 28, 2010
Base term plus 63 days of patent term adjustment (USPTO delay)
Today
20 years from filing
Ended no later than Jun 2, 2026
2006 2026
Clock starts
Mar 31, 2006
Ended no later than
Jun 2, 2026
Granted
Dec 28, 2010
base term patent term adjustment after the term ends fee events Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
63
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
20
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term runs 63 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees were paid, so no fee lapse ended it. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Mar 31, 2006, when application 11/396,328, the earliest non-provisional in its chain, was filed (this one was filed Jan 20, 2009)Mar 31, 2026High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+63 days, USPTO patent term adjustment recordJun 2, 2026High confidence
Terminal disclaimer capDisclaimer on file (approved), reference document not resolvedno cap applied, and none guessedMedium confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events3 of 3 maintenance fees paidterm endedHigh confidence
Computed term endThe steps above, in orderno later than Jun 2, 2026Medium confidence

This family

US 7,736,905In force
Mar 2028
Mar 2028
Application PCT/US2007/007467PCT application
no patent term
no patent term
US 8,024,282In force
Feb 2028
Feb 2028
Application 61/191,927Provisional application
no patent term
no patent term
US 7,858,390Lapsed on the fee record
Dec 2022
Dec 2022
US 7,858,389this patent
no later than Jun 2026
no later than Jun 2026
US 7,867,775Term ended
Mar 2026
Mar 2026
US 7,906,342Term ended
no later than May 2026
no later than May 2026
8 of 20 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Mar 2, 2009
Reel 22348, frame 985
Roeder, Heinrich; Tsypin, Maxim; Grigorieva, JuliaBiodesix, Inc.Assignment of Assignor's Interest
Dec 3, 2013
reel/frame not recorded
Biodesix, Inc.Capital Royalty Partners II L.P.Short-Form Patent Security Agreement
Dec 3, 2013
reel/frame not recorded
Biodesix, Inc.Capital Royalty Partners II - Parallel Fund "a" L.P.Short-Form Patent Security Agreement
Dec 3, 2013
reel/frame not recorded
Biodesix, Inc.Parallel Investment Opportunities Partners II L.P.Short-Form Patent Security Agreement
Dec 3, 2013
Reel 31751, frame 694
Biodesix, Inc.Capital Royalty Partners II L.P.; Capital Royalty Partners II - Parallel Fund "a" L.P.; Parallel Investment Opportunities Partners II L.P.Short-Form Patent Security Agreement
Feb 2, 2018
Reel 44813, frame 947
Roder, Heinrich; Tsypin, Maxim; Grigorieva, JuliaBiodesix Inc.Assignment of Assignor's Interest
Feb 23, 2018
Reel 45022, frame 976
Biodesix, Inc.Innovatus Life Sciences Lending Fund I, LP, as Collateral AgentSecurity Interest
Feb 27, 2018
Reel 45450, frame 503
Capital Royalty Partners II L.P.; Capital Royalty Partners II - Parallel Fund "a" L.P.; Parallel Investment Opportunities Partners II L.P.Biodesix, Inc.Security Interest
Apr 12, 2018
Reel 45922, frame 171
Capital Royalty Partners II L.P.; Capital Royalty Partners II - Parallel Fund "a" L.P.; Parallel Investment Opportunities Partners II L.P.Biodesix, Inc.Corrective Assignment to Correct the Nature of Conveyance Previously Recorded on Reel 045450 Frame 0503. Assignor(S) Hereby Confirms the Release of Security Interest.
Mar 19, 2021
Reel 55657, frame 911
Innovatus Life Sciences Lending Fund I, LP, as Collateral AgentBiodesix, Inc.Release of Security Interest
Nov 22, 2022
Reel 61977, frame 919
Biodesix, Inc.Perceptive Credit Holdings IV, LPSecurity Agreement

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited